glycolipid transfer protein domain containing 2Genealiases: []
Q-omics provides the consensus-scored GLTPD2 profile across patient tissues and cancer cell-line models. GLTPD2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GLTPD2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, GLTPD2 RNA expression shows 19,172 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where GLTPD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLTPD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLTPD2 survival associations across molecular data types. GLTPD2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLTPD2 RNA expression–survival associations across cancer types. High GLTPD2 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, HNSC, OV, SCLC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GLTPD2 RNA expression.
This table summarizes GLTPD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GLTPD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLTPD2 shows lower tumor expression in THCA, KICH, KIRP, CHOL and LIHC and higher tumor expression in COAD. The THCA box plot shows higher GLTPD2 RNA expression in normal versus tumor tissue (log2 FC = −1.061, t-test p < 0.001).
This table shows molecular features associated with GLTPD2 in patient tissues and cancer cell lines. In patient samples, GLTPD2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GLTPD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
